Haemonetics (HAE) Stock
Global blood management specialist serving hospitals and blood banks. Here's the price, business snapshot, and what's worth knowing about Haemonetics in October 2026.
Haemonetics Corporation (HAE) supplies blood- and plasma-management systems, disposables and software to hospitals, blood centres and plasma collectors worldwide. Investors should know the business mixes recurring revenue from consumables with equipment sales and service contracts, which can provide revenue visibility but is sensitive to procedure volumes and reimbursement. The company competes on product innovation, supply reliability and regulatory compliance; acquisitions and new product roll-outs can support growth but also carry execution risk. Key risks include regulatory change, reimbursement pressure, cyclic healthcare spending and competition from larger medical-device companies. With a market capitalisation around $2.47bn, HAE can appeal to those seeking exposure to specialised medical devices, though it may be more volatile than large-cap healthcare names. This is general educational information, not personal advice — values can rise and fall and returns are not guaranteed. Consult your financial adviser to assess whether this stock fits your objectives and risk tolerance.
Haemonetics (HAE) Stock Forecast
Analyst price target, next 12 months
$127.71
+7.6% vs today's $118.69
Price range over the last 12 months
Close to its 12-month high
Analysts covering Haemonetics have a consensus 12-month target of $127.71, above the current price of $118.69.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 12 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Haemonetics stock with a target price of $127.71, indicating growth potential.
Financial Health
Haemonetics is performing well with strong revenue and cash flow, indicating healthy financial stability.
Dividend
Haemonetics Corp offers a dividend yield of 2%, making it a reasonable choice if you seek dividend income. If you invested $1000 you would be paid $20 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Recurring Revenue Mix
Consumables and service contracts provide steady revenue streams, offering predictability, though performance can vary with procedure volumes and reimbursement.
Product Innovation Focus
New devices and software can drive market share and margins, but R&D, regulatory approval and execution risk can affect outcomes.
Global Market Exposure
A presence across hospitals and blood centres gives geographic diversification, yet differing regulations and healthcare budgets can create varied performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
